ESR1 and triple-negative breast carcinoma: YAP overexpression have been reported in some type of breast cancer including Luminal or ER+ (estrogen receptor α positive) subtypes, HER2-enriched tumours, and in triple-negative breast cancer (Kim et al., 2014; Lehn et al., 2014; Min Kim et al., 2015).